RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease

被引:51
|
作者
Mandigo, Amy C. [1 ]
Yuan, Wei [2 ,3 ]
Xu, Kexin [4 ]
Gallagher, Peter [1 ]
Pang, Angel [5 ,6 ]
Guan, Yi Fang [5 ,6 ]
Shafi, Ayesha A. [1 ]
Thangavel, Chellappagounder [7 ,8 ,9 ,10 ,11 ]
Sheehan, Beshara [2 ,3 ]
Bogdan, Denisa [2 ,3 ]
Paschalis, Alec [2 ,3 ]
McCann, Jennifer J. [1 ]
Laufer, Talya S. [1 ]
Gordon, Nicolas [1 ]
Vasilevskaya, Irina A. [1 ]
Dylgjeri, Emanuela [1 ]
Chand, Saswati N. [1 ]
Schiewer, Matthew J. [1 ]
Domingo-Domenech, Josep [1 ]
Den, Robert B. [1 ,7 ,8 ,9 ,11 ]
Holst, Jeff [5 ,6 ]
McCue, Peter A. [1 ,11 ]
de Bono, Johann S. [2 ,3 ]
McNair, Christopher [1 ,11 ]
Knudsen, Karen E. [1 ,7 ,8 ,9 ,11 ]
机构
[1] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA
[2] Inst Canc Res, London, England
[3] Royal Marsden NHS Fdn Trust, London, England
[4] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[5] Univ New South Wales, Sch Med Sci, Sydney, NSW, Australia
[6] Univ New South Wales, Prince Wales Clin Sch, Sydney, NSW, Australia
[7] Thomas Jefferson Univ, Dept Urol, Philadelphia, PA 19107 USA
[8] Thomas Jefferson Univ, Dept Med Oncol, Philadelphia, PA 19107 USA
[9] Thomas Jefferson Univ, Dept Radiat Oncol, Philadelphia, PA 19107 USA
[10] Thomas Jefferson Univ, Dept Dermatol, Philadelphia, PA 19107 USA
[11] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA
关键词
TUMOR-SUPPRESSOR STATUS; AMINO-ACID-TRANSPORT; BREAST-CANCER; THERAPEUTIC RESPONSE; RETINOBLASTOMA GENE; RB-PATHWAY; EXPRESSION; CYCLE; INHIBITION; RECEPTOR;
D O I
10.1158/2159-8290.CD-20-1114
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Loss of the retinoblastoma (RB) tumor suppressor protein is a critical step in reprogramming biological networks that drive cancer progression, although mechanistic insight has been largely limited to the impact of RB loss on cell-cycle regulation. Here, isogenic modeling of RB loss identified disease stage-specific rewiring of E2F1 function, providing the first-in-field mapping of the E2F1 cistrome and transcriptome after RB loss across disease progression. Biochemical and functional assessment using both in vitro and in vivo models identified an unexpected, prominent role for E2F1 in regulation of redox metabolism after RB loss, driving an increase in the synthesis of the antioxidant glutathione, specific to advanced disease. These E2F1-dependent events resulted in protection from reactive oxygen species in response to therapeutic intervention. On balance, these findings reveal novel pathways through which RB loss promotes cancer progression and highlight potentially new nodes of intervention for treating RB-deficient cancers. SIGNIFICANCE: This study identifies stage-specific consequences of RB loss across cancer progression that have a direct impact on tumor response to clinically utilized therapeutics. The study herein is the first to investigate the effect of RB loss on global metabolic regulation and link RB/E2F1 to redox control in multiple advanced diseases.
引用
收藏
页码:2334 / 2353
页数:20
相关论文
共 50 条
  • [31] Cancer-testis specific gene OIP5: a downstream gene of E2F1 that promotes tumorigenesis and metastasis in glioblastoma by stabilizing E2F1 signaling
    He, Jiang
    Zhao, Yuzu
    Zhao, Erhu
    Wang, Xianxing
    Dong, Zhen
    Chen, Yibiao
    Yang, Liqun
    Cui, Hongjuan
    NEURO-ONCOLOGY, 2018, 20 (09) : 1173 - 1184
  • [32] ATPR regulates human mantle cell lymphoma cells differentiation via SOX11/CyclinD1/Rb/E2F1
    Xu, Xiaoling
    Zhang, Tao
    Zhang, Meiju
    Li, Lanlan
    Deng, Ge
    Lu, Zheng
    Zhang, Zhenyu
    Du, Yan
    Feng, Yubin
    Feng, Xiaowen
    Peng, Xiaoqing
    Chen, Feihu
    CELLULAR SIGNALLING, 2022, 93
  • [33] TFDP3 was expressed in coordination with E2F1 to inhibit E2F1-mediated apoptosis in prostate cancer
    Ma, Yueyun
    Xin, Yijuan
    Li, Rui
    Wang, Zhe
    Yue, Qiaohong
    Xiao, Fengjing
    Hao, Xiaoke
    GENE, 2014, 537 (02) : 253 - 259
  • [34] lncRNA-HIT promotes cell proliferation of non-small cell lung cancer by association with E2F1
    Yu, L.
    Fang, F.
    Lu, S.
    Li, X.
    Yang, Y.
    Wang, Z.
    CANCER GENE THERAPY, 2017, 24 (05) : 221 - 226
  • [35] The E2F1/DNMT1 Axis Is Associated With the Development of AR Negative Castration Resistant Prostate Cancer
    Valdez, Conrad David
    Kunju, Lakshmi
    Daignault, Stephanie
    Wojno, Kirk J.
    Day, Mark L.
    PROSTATE, 2013, 73 (16): : 1776 - 1785
  • [36] E2F1 Suppresses Oxidative Metabolism and Endothelial Differentiation of Bone Marrow Progenitor Cells
    Xu, Shiyue
    Tao, Jun
    Yang, Liu
    Zhang, Eric
    Boriboun, Chan
    Zhou, Junlan
    Sun, Tianjiao
    Cheng, Min
    Huang, Kai
    Shi, Jiawei
    Dong, Nianguo
    Liu, Qinghua
    Zhao, Ting C.
    Qiu, Hongyu
    Harris, Robert A.
    Chandel, Navdeep S.
    Losordo, Douglas W.
    Qin, Gangjian
    CIRCULATION RESEARCH, 2018, 122 (05) : 701 - 711
  • [37] Antitumor effect of lapatinib and cytotoxic agents by suppression of E2F1 in HER2-positive breast cancer
    Matsumoto, Akiko
    Hayashida, Tetsu
    Takahashi, Maiko
    Jinno, Hiromitsu
    Kitagawa, Yuko
    MOLECULAR MEDICINE REPORTS, 2018, 18 (01) : 958 - 964
  • [38] The HMGA1 protoncogene frequently deregulated in cancer is a transcriptional target of E2F1
    Massimi, Isabella
    Guerrieri, Francesca
    Petroni, Marialaura
    Veschi, Veronica
    Truffa, Silvia
    Screpanti, Isabella
    Frati, Luigi
    Levrero, Massimo
    Gulino, Alberto
    Giannini, Giuseppe
    MOLECULAR CARCINOGENESIS, 2013, 52 (07) : 526 - 534
  • [39] E2F1 and E2F7 regulate gastric cancer cell proliferation respectively, through transcriptional activation and transcriptional repression of MYBL2
    Wu, Tianyi
    Jiang, Fengli
    Wu, Fan
    Zheng, Guoliang
    Li, Yang
    Wu, Lizhao
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2025, 301 (01)
  • [40] E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter
    Chu, Junjun
    Zhu, Yinghua
    Liu, Yujie
    Sun, Lijuan
    Lv, Xiaobin
    Wu, Yanqin
    Hu, Pengnan
    Su, Fengxi
    Gong, Chang
    Song, Erwei
    Liu, Bodu
    Liu, Qiang
    ONCOTARGET, 2015, 6 (31) : 31944 - 31957